{"doi":"10.7326/m23-0641","title":"Pharmacologic Treatment Initiation Among Medicare Beneficiaries Hospitalized With Alcohol Use Disorder","abstract":"LettersAugust 2023Pharmacologic Treatment Initiation Among Medicare Beneficiaries Hospitalized With Alcohol Use DisorderCorrection(s) for this article:Corrections29 Aug 2023Correction: Pharmacologic Treatment Initiation Among Medicare Beneficiaries Hospitalized With Alcohol Use DisorderFREEEden Y. Bernstein, MD, Travis P. Baggett, MD, MPH, Shrunjal Trivedi, MPH, Shoshana J. Herzig, MD, MPH, Timothy S. Anderson, MD, MASEden Y. Bernstein, MDDivision of General Internal Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, Travis P. Baggett, MD, MPHDivision of General Internal Medicine, Massachusetts General Hospital; Harvard Medical School; and Institute for Research, Quality, and Policy in Homeless Health Care, Boston Health Care for the Homeless Program, Boston, Massachusetts, Shrunjal Trivedi, MPHDivision of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Shoshana J. Herzig, MD, MPHHarvard Medical School and Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Timothy S. Anderson, MD, MASHarvard Medical School and Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MassachusettsAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M23-0641 Annals Author Insight Video - Eden Y. Bernstein, MD In this video, Eden Y. Bernstein, MD, offers additional insight into the article, \"Pharmacologic Treatment Initiation Among Medicare Beneficiaries Hospitalized With Alcohol Use Disorder.\" (Duration 2:36) SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: In the United States, 29 million adults have alcohol use disorder (AUD), and alcohol contributes to more than 140 000 deaths annually (1). Hospitalizations provide an opportunity to promote behavior change by initiating treatment with medications for AUD (MAUD), including naltrexone, acamprosate, and disulfiram, which have been approved by the U.S. Food and Drug Administration for decades (2). Low prescribing rates for hospitalized patients have been observed in single-center studies, but nationwide data on MAUD treatment initiation after hospitalization are lacking (3).Objective: To characterize MAUD treatment initiation after AUD hospitalizations using the 20% national sample of Medicare Part D ...References1. National Institute on Alcohol Abuse and Alcoholism. Alcohol facts and statistics. Accessed at www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics on 3 August 2022. Google Scholar2. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86-90. [PMID: 29301420] doi:10.1176/appi.ajp.2017.1750101 CrossrefMedlineGoogle Scholar3. Martin M, Clement J, Defries T, et al. Prevalence and characteristics of hospitalizations with unhealthy alcohol use in a safety-net hospital from 2016 to 2018. J Gen Intern Med. 2022;37:3211-3213. [PMID: 35060005] doi:10.1007/s11606-021-07357-5 CrossrefMedlineGoogle Scholar4. Kim HM, Smith EG, Stano CM, et al. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res. 2012;12:18. [PMID: 22270080] doi:10.1186/1472-6963-12-18 CrossrefMedlineGoogle Scholar5. Bernstein E, Guo N, Goto T, et al. Characterizing the variation of alcohol cessation pharmacotherapy in primary care. J Gen Intern Med. 2021;36:1989-1996. [PMID: 33515195] doi:10.1007/s11606-020-06454-1 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Eden Y. Bernstein, MD; Travis P. Baggett, MD, MPH; Shrunjal Trivedi, MPH; Shoshana J. Herzig, MD, MPH; Timothy S. Anderson, MD, MASAffiliations: Division of General Internal Medicine, Massachusetts General Hosp","journal":"Annals of Internal Medicine","year":2023,"id":326195,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":29,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9486,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":402427,"name":"Travis P. Baggett","orcid":"0000-0002-7032-2625","position":1,"is_corresponding":false},{"id":1045748,"name":"Shrunjal Trivedi","orcid":null,"position":2,"is_corresponding":false},{"id":351916,"name":"Shoshana J. Herzig","orcid":"0000-0001-8005-4727","position":3,"is_corresponding":false},{"id":395133,"name":"Timothy S. Anderson","orcid":"0000-0002-5384-275X","position":4,"is_corresponding":false},{"id":1045747,"name":"Eden Y. Bernstein","orcid":null,"position":0,"is_corresponding":true}],"reference_count":4,"raw_metadata":null,"created_at":"2026-07-19T01:08:33.106703Z","pmid":"37364264","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}